Patent · US Active

Methods of using chimeric antigen receptors targeting B-cell maturation antigen and uses thereof

US11000549B2 · kind B2 · utility

4Cited by
9References
20Claims
0Family size

Assignees

Inventors

Key dates

Filing dateApr 9, 2020
Grant dateMay 11, 2021
Priority date
Expiry dateApr 9, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2840/203
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target B cell maturation antigen (BMCA), and immunoresponsive cells comprising such CARs. The presently disclosed BMCA-specific CARs have enhanced immune-activating properties, including anti-tumor activity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.